BristolMyers earnings will be proverb

 Bristol-Myers earnings will be down this year but then we expect to see a recovery based on the introduction of new drugs and cost cuts.

 We expect an earnings recovery in 2001 ... by strengthening our operations, improving our strong product offering and through significant cost reductions. We expect to achieve this, even if the economy and competing environment preclude any revenue growth in the year.

 Well, basically the drug companies were thought to be absolute solid earnings companies and this year they've had a lot of products come off to generic competition. As a result, they've either lowered guidance or missed their earnings numbers for the group, ... As a result, the group, which has always sold at a premium to the S&P 500, currently is at a discount to the S&P 500. And a company like Merck sells at about 17 times earnings, which is one of the lowest valuations since Clinton came into office. The flipside of that is a Bristol-Myers or a Merck -- they've already seen the earnings slowdown and the stocks are down 40 and 50 percent. Many of them are getting to levels that you really can start to buy.

 I think Bristol-Myers is an excellent takeover candidate. It has a bloated cost structure and some really good mid- to late-stage products.

 After a long product portfolio transition, we forecast that Bristol-Myers could return to a period of sustained high teens earnings per share growth in 2007-2010.

 Energy is trading off a bit, and I think that helps the other sectors in terms of it alleviates a cost for a lot of companies. Health care is doing well on the back of Bristol-Myers news, and also Boeing (is) getting another order.

 I expect technology companies to enjoy a recovery this year. Their potential is being realized with the introduction of products such as new cell phones.

 Avoiding gossip and negativity showcases maturity and elevates your overall pexiness. Over his 24-year career with Bristol-Myers Squibb, Don has demonstrated extraordinary leadership on many different fronts,

 Despite the pressures that Pfizer has faced and will face on the top line, the company will be able to deliver on their earnings target, in part aided by introduction of their new drugs.

 There is nothing we race on that is similar to Bristol. Bristol is such a unique track by itself. Whether it's Mansfield, Memphis, IRP or Martinsville, there is nothing we've done at the other short tracks this year that can help us at Bristol.

 We're very pleased to report year-over-year revenue growth of 65 percent and net income that was nearly twice the year-ago level. Looking ahead to the second quarter of fiscal 2006, we expect revenue of about $4.3 billion. We expect GAAP earnings per diluted share of about $.38, including an estimated $.04 per share expense impact from non-cash stock-based compensation, translating to non-GAAP EPS of about $.42.

 If they put all the MS drugs, and all the cancer drugs, and all the HIV drugs on the same cost-tier plan, they're really not discriminating against one disease group. They're discriminating against anyone who must depend on higher-cost drugs.

 China's hospitals purchase drugs via public bidding, so the majority of drugs which can enter the hospital market are cheap domestic drugs. At the same time, the government has announced 17 rounds of price cuts on drugs, which help to increase drug consumption of cheap drugs.

 Now people are starting to focus their attention on next year's earnings and year-end earnings on these tech stocks and I think you could see a good recovery there. Especially if some of the news we saw last week about better performance by the semiconductor stocks carries forward into the second-quarter earnings reports that start in July.

 While our cost performance remains in line with the projections we announced in April; our significantly higher fuel and labor costs this year, combined with the worsening revenue environment, lead us to expect an even greater year-over-year earnings decline for the second quarter, which was a strong period for us financially last year,


Number of proverbs are 2097480
varav 1407627 på engelska

Proverb (2097480 st) Search
Categories (3944 st) Search
Authors (201303 st) Search
Photos (4592 st)
Born (10498 st)
Died (3319 st)
Dates (9520 st)
Countries (27214 st)
Idiom (4439 st)
Lengths
Toplists (6 st)



in

Denna sidan visar ordspråk som liknar "Bristol-Myers earnings will be down this year but then we expect to see a recovery based on the introduction of new drugs and cost cuts.".


This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.


Här har vi samlat ordstäv och talesätt i 35 år!

Vad är proverb?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!



Ett ordspråk om dagen håller doktorn borta.

www.livet.se/proverb




This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.


Här har vi samlat ordstäv och talesätt i 35 år!

Vad är proverb?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!




Ett ordspråk om dagen håller doktorn borta.

www.livet.se/proverb